Biosimilar Monoclonal Antibody Market By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), By Indication (Oncology, Autoimmune diseases, Others), By End User (Hospitals, Cancer treatment centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Biosimilar Monoclonal Antibody Market

The Biosimilar Monoclonal Antibody Market is likely to experience a significant growth rate of 22.2% from 2023-2032 owing to increasing demand for novel therapeutics from pharmaceutical sector –

A biosimilar monoclonal antibody is a highly similar version of a reference monoclonal antibody drug that has demonstrated comparable efficacy, safety and quality. Developed through advanced biotechnology, biosimilar mAbs offer cost-effective alternatives to the original reference product, expanding patient access to essential treatments while maintaining regulatory standards. Key factors driving the growth of the biosimilar monoclonal antibody market are rising prevalence of chronic disorders, rise in regulatory approvals and increasing adoption of biosimilars. The rising prevalence of chronic diseases such as cancer, autoimmune disorders and inflammatory conditions, has driven the demand for effective therapeutic options. Biosimilar monoclonal antibodies have emerged as viable alternatives to reference biologics, addressing unmet medical needs and providing physicians with additional treatment choices. Thus, as the global prevalence of chronic diseases continues to increase, the market for biosimilar monoclonal antibodies is expected to witness sustained growth.

In addition, biosimilar offer significant cost savings as compared to reference biologics, thereby driving the market growth. Biologic therapies are often associated with high costs, limiting patient access. Biosimilars offer a cost-effective alternative, allowing healthcare systems to allocate resources more efficiently and expand patient access to life-saving treatments. This cost advantage enhances the adoption of biosimilar monoclonal antibodies, particularly in regions with budget constraints. Further, in both developed and developing countries, there is a growing demand for affordable biologic therapies. Biosimilar monoclonal antibodies offer a treatment option to bridge the gap between the high cost of biologics and patients need for accessible treatment options. This demand-driven market dynamic propels the development and commercialization of biosimilars, fostering competition and promoting equitable healthcare access.

Furthermore, physician and patient acceptance is crucial for the success of biosimilar monoclonal antibodies. Healthcare professionals are increasingly open to prescribing biosimilars owing to robust clinical data demonstrating their therapeutic equivalence. Patient advocacy groups and educational initiatives have also played a role in dispelling misconceptions about biosimilars, building trust and encouraging patients to opt for these more affordable treatment options, thus propelling the market growth. Moreover, regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have played a pivotal role in fostering the growth of the biosimilar monoclonal antibody market. Evolving guidelines and regulatory pathways have facilitated streamlined approval processes for biosimilars, reducing the barriers to entry for manufacturers. For instance, in December 2020, Amgen announced that the U.S. Food and Drug Administration (FDA) approved RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). This environment encourages competition, leading to increased availability and affordability of biosimilar monoclonal antibodies. 

Emerging markets present a significant growth opportunity for biosimilar monoclonal antibodies. These regions often struggle to provide access to high-cost biologic therapies. Biosimilars offer a solution by providing affordable treatment options, addressing unmet medical needs, and improving healthcare access. The strategic entry into these markets further contributes to the expansion of the biosimilar monoclonal antibody market. 

Further, rise in the number of clinical studies for development of biosimilar is expected to fuel the market growth. For instance, in January 2021, Shanghai Henlius Biotech, Inc., announced that the filing of clinical trial for HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody ophthalmic injection, for the treatment of wet age-related macular degeneration (wAMD) has been approved by the Therapeutic Goods Administration, Australia. Thus, such approvals for clinical studies are expected to propel the market expansion.

The biosimilar monoclonal antibody market is segmented on the type, indication, end user and region. On the basis of type, the market is categorized into adalimumab, bevacizumab, infliximab, rituximab, trastuzumab, and others. On the basis of indication, the market is classified into oncology, autoimmune diseases, and others. On the basis of end user, the market is segmented into hospitals, cancer treatment centers and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The key players profiled in the study include Novartis AG, Pfizer Inc., Amgen Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Limited, Shanghai Henlius Biotech, Inc., BIOCAD, Biogen, Biocon, and Celltrion Healthcare Co., Ltd. The key players have adopted strategies such as collaboration, product launch, agreement, clinical trial approval, acquisition, and product approval to expand their product portfolio.

Key Market Insights

On the basis of type, the adalimumab segment dominated the market in terms of revenue in 2022, and is expected to witness highest CAGR during the forecast period.

On the basis of indication, the oncology segment dominated the market in terms of revenue in 2022.

Based on the end user, the hospitals segment dominated the market in terms of revenue in 2022.

Region-wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The biosimilar monoclonal antibody market was valued for $8,727.00 million in 2022 and is estimated to reach $64,699.19 million by 2032, exhibiting a CAGR of 22.2% from 2023 to 2032. Biosimilar monoclonal antibodies are biologic treatments that closely resemble established reference monoclonal antibodies, commonly referred to as originator or innovator monoclonal antibodies. These similarities encompass aspects such as structure, function, effectiveness, safety, and quality. Monoclonal antibodies (mAbs) are large proteins produced in living cells and are designed to target specific molecules or cells in the body involved in disease processes. Biosimilar monoclonal antibodies find application in a range of therapeutic areas, including oncology, immunology, and infectious diseases. Biosimilar monoclonal antibodies are produced by different manufacturers other than the originator product but demonstrate no clinically meaningful differences from the reference product. They undergo rigorous analytical and clinical testing to establish their similarity with reference biosimilars and demonstrate safety and efficacy. 

The major factors driving the growth of biosimilar monoclonal antibody market are increasing demand for biosimilar mAbs, supportive regulatory environment, and increase in patent expirations of blockbuster monoclonal antibodies. Monoclonal antibodies and similar biologic medications have emerged as essential choices for addressing a variety of persistent and intricate health conditions, including cancer, autoimmune disorders, and inflammatory issues. Rise in prevalence of these diseases, coupled with the increasing aging population, has led to a higher demand for biologics, including biosimilar mAbs. In addition, biosimilar mAbs are generally more cost-effective than their originator counterparts. As the innovative monoclonal antibodies are highly costly, healthcare providers and payers are increasingly seeking cost-saving options without compromising on therapeutic efficacy. Biosimilars offer a more affordable treatment option, which can lead to increase in adoption in both, developed and developing markets.

Furthermore, due to patent expirations and advancements in biotechnological research, manufacturers of biosimilars have had the opportunity to investigate fresh therapeutic applications for their offerings. This widens the potential applications of biosimilar mAbs. Furthermore, increase in the number of biosimilar manufacturers and their willingness to invest in R&D and production capabilities have intensified competition in the biosimilar mAbs market, which contributes to lowering prices and enhancing overall market penetration. Moreover, regulatory agencies in many countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established clear guidelines for the approval of biosimilar products. These guidelines provide a transparent pathway for development, testing, and approval of biosimilar mAbs, which boosts the confidence of manufacturers entering the market.

The biosimilar monoclonal antibody market is segmented on the type, indication, end user and region. On the basis of type, the market is categorized into adalimumab, bevacizumab, infliximab, rituximab, trastuzumab, and others. On the basis of indication, the market is classified into oncology, autoimmune diseases, and others. On the basis of end user, the market is segmented into hospitals, cancer treatment centers and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global biosimilar monoclonal antibody market are Novartis AG, Pfizer Inc., Amgen Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Limited, Shanghai Henlius Biotech, Inc., BIOCAD, Biogen, Biocon, and Celltrion Healthcare Co., Ltd. The key players have adopted strategies such as collaboration, product launch, agreement, clinical trial approval, acquisition, and product approval to expand their product portfolio.

Key Benefits for Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimilar monoclonal antibody market analysis from 2022 to 2032 to identify the prevailing biosimilar monoclonal antibody market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the biosimilar monoclonal antibody market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global biosimilar monoclonal antibody market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● SWOT Analysis

Key Market Segments

○ Bioge

Scope of Biosimilar Monoclonal Antibody Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. High bargaining power of suppliers

3.3.2. High threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. High bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of chronic diseases

3.4.1.2. Rise in number of product approvals for biosimilar monoclonal antibodies

3.4.1.3. Expiration of patents

3.4.2. Restraints

3.4.2.1. Intellectual property and legal challenges

3.4.3. Opportunities

3.4.3.1. Growing opportunities in emerging markets

3.4.3.2. Increase in number of pipeline drugs

4.1. Overview

4.1.1. Market size and forecast

4.2. Adalimumab

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Bevacizumab

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Infliximab

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Rituximab

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Trastuzumab

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities

4.7.2. Market size and forecast, by region

4.7.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Autoimmune diseases

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Cancer treatment centers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Type

7.2.3. Market size and forecast, by Indication

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Type

7.2.5.1.2. Market size and forecast, by Indication

7.2.5.1.3. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Type

7.2.5.2.2. Market size and forecast, by Indication

7.2.5.2.3. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Type

7.2.5.3.2. Market size and forecast, by Indication

7.2.5.3.3. Market size and forecast, by End User

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Type

7.3.3. Market size and forecast, by Indication

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Type

7.3.5.1.2. Market size and forecast, by Indication

7.3.5.1.3. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Type

7.3.5.2.2. Market size and forecast, by Indication

7.3.5.2.3. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Type

7.3.5.3.2. Market size and forecast, by Indication

7.3.5.3.3. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Type

7.3.5.4.2. Market size and forecast, by Indication

7.3.5.4.3. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Type

7.3.5.5.2. Market size and forecast, by Indication

7.3.5.5.3. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Type

7.3.5.6.2. Market size and forecast, by Indication

7.3.5.6.3. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Type

7.4.3. Market size and forecast, by Indication

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Type

7.4.5.1.2. Market size and forecast, by Indication

7.4.5.1.3. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Type

7.4.5.2.2. Market size and forecast, by Indication

7.4.5.2.3. Market size and forecast, by End User

7.4.5.3. India

7.4.5.3.1. Market size and forecast, by Type

7.4.5.3.2. Market size and forecast, by Indication

7.4.5.3.3. Market size and forecast, by End User

7.4.5.4. Australia

7.4.5.4.1. Market size and forecast, by Type

7.4.5.4.2. Market size and forecast, by Indication

7.4.5.4.3. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Type

7.4.5.5.2. Market size and forecast, by Indication

7.4.5.5.3. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Type

7.4.5.6.2. Market size and forecast, by Indication

7.4.5.6.3. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Type

7.5.3. Market size and forecast, by Indication

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Type

7.5.5.1.2. Market size and forecast, by Indication

7.5.5.1.3. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Type

7.5.5.2.2. Market size and forecast, by Indication

7.5.5.2.3. Market size and forecast, by End User

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Type

7.5.5.3.2. Market size and forecast, by Indication

7.5.5.3.3. Market size and forecast, by End User

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Type

7.5.5.4.2. Market size and forecast, by Indication

7.5.5.4.3. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Pfizer Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Amgen Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Novartis AG

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Coherus BioSciences, Inc.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Teva Pharmaceutical Industries Limited

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Shanghai Henlius Biotech, Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. BIOCAD

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.8. Biocon

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Celltrion Healthcare Co., Ltd.

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Biogen

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 02. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ADALIMUMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 03. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR BEVACIZUMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 04. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR INFLIXIMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 05. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR RITUXIMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 06. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR TRASTUZUMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 07. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 09. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)

TABLE 10. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 13. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)

TABLE 14. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022-2032 ($MILLION)

TABLE 15. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 16. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 19. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 20. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 21. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 22. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 23. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 24. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 25. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 26. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 27. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 28. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 29. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 30. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 31. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 32. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 33. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 34. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 35. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 36. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 37. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 38. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 39. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 40. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 41. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 42. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 43. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 44. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 45. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 46. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 47. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 48. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 49. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 50. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 51. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 53. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 54. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 55. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 56. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 57. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 58. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 59. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 60. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 61. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 62. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 63. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 64. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 65. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 66. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 67. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 68. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 69. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 70. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 72. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 73. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 74. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 75. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 76. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 77. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 78. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 79. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 80. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 81. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 82. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 83. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 84. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 85. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 86. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 87. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 88. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 89. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 90. PFIZER INC.: KEY EXECUTIVES

TABLE 91. PFIZER INC.: COMPANY SNAPSHOT

TABLE 92. PFIZER INC.: PRODUCT SEGMENTS

TABLE 93. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 94. PFIZER INC.: KEY STRATERGIES

TABLE 95. AMGEN INC.: KEY EXECUTIVES

TABLE 96. AMGEN INC.: COMPANY SNAPSHOT

TABLE 97. AMGEN INC.: PRODUCT SEGMENTS

TABLE 98. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 99. AMGEN INC.: KEY STRATERGIES

TABLE 100. NOVARTIS AG: KEY EXECUTIVES

TABLE 101. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 102. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 103. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 104. NOVARTIS AG: KEY STRATERGIES

TABLE 105. COHERUS BIOSCIENCES, INC.: KEY EXECUTIVES

TABLE 106. COHERUS BIOSCIENCES, INC.: COMPANY SNAPSHOT

TABLE 107. COHERUS BIOSCIENCES, INC.: PRODUCT SEGMENTS

TABLE 108. COHERUS BIOSCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 109. COHERUS BIOSCIENCES, INC.: KEY STRATERGIES

TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 115. SHANGHAI HENLIUS BIOTECH, INC.: KEY EXECUTIVES

TABLE 116. SHANGHAI HENLIUS BIOTECH, INC.: COMPANY SNAPSHOT

TABLE 117. SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT SEGMENTS

TABLE 118. SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT PORTFOLIO

TABLE 119. SHANGHAI HENLIUS BIOTECH, INC.: KEY STRATERGIES

TABLE 120. BIOCAD: KEY EXECUTIVES

TABLE 121. BIOCAD: COMPANY SNAPSHOT

TABLE 122. BIOCAD: PRODUCT SEGMENTS

TABLE 123. BIOCAD: PRODUCT PORTFOLIO

TABLE 124. BIOCON: KEY EXECUTIVES

TABLE 125. BIOCON: COMPANY SNAPSHOT

TABLE 126. BIOCON: PRODUCT SEGMENTS

TABLE 127. BIOCON: PRODUCT PORTFOLIO

TABLE 128. BIOCON: KEY STRATERGIES

TABLE 129. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES

TABLE 130. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT

TABLE 131. CELLTRION HEALTHCARE CO., LTD.: PRODUCT SEGMENTS

TABLE 132. CELLTRION HEALTHCARE CO., LTD.: PRODUCT PORTFOLIO

TABLE 133. CELLTRION HEALTHCARE CO., LTD.: KEY STRATERGIES

TABLE 134. BIOGEN: KEY EXECUTIVES

TABLE 135. BIOGEN: COMPANY SNAPSHOT

TABLE 136. BIOGEN: PRODUCT SEGMENTS

TABLE 137. BIOGEN: PRODUCT PORTFOLIO

TABLE 138. BIOGEN: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMILAR MONOCLONAL ANTIBODY MARKET (2023-2032)

FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 05. HIGH THREAT OF NEW ENTRANTS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. HIGH BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ADALIMUMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR BEVACIZUMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR INFLIXIMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR RITUXIMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR TRASTUZUMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, 2022 AND 2032(%)

FIGURE 26. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 27. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 28. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 29. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 30. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 31. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 32. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 33. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 34. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 35. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 36. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 37. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 38. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 39. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 40. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 41. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 42. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 43. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 44. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 49. COMPETITIVE DASHBOARD

FIGURE 50. COMPETITIVE HEATMAP: BIOSIMILAR MONOCLONAL ANTIBODY MARKET

FIGURE 51. TOP PLAYER POSITIONING, 2022

FIGURE 52. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 56. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 61. COHERUS BIOSCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 64. SHANGHAI HENLIUS BIOTECH, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 65. SHANGHAI HENLIUS BIOTECH, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 66. BIOCON: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 67. BIOCON: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. CELLTRION HEALTHCARE CO., LTD.: NET SALES, 2020-2022 ($MILLION)

FIGURE 69. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 70. BIOGEN: REVENUE SHARE BY REGION, 2022 (%